Starting a new treatment for my MS tomorrow — answering your questions
A patient with progressive multiple sclerosis shares his experience starting a pectin treatment, caught between conventional medicine and alternative therapies.
English · Original discussion in Spanish · Published
New treatment for pogre multiple sclerosis: between conventional and alternative
A patient diagnosed with primary pogre multiple sclerosis (PPMS) starts a pectin treatment tomorrow to slow cognitive decline. The diagnosis came after a subtle symptom in 2022: dragging his right foot while working. Since then, he has received Ocrelizumab (Ocrevus), a monoclonal antibody that slows the disease but fails to stop its pogre. PPMS affects roughly 15% of multiple sclerosis patients and is characterized by continuous worsening without clear relapses.
Ocrelizumab: limited effectiveness in the pogre form
Ocrelizumab is the only drug approved for PPMS, but its effectiveness is modest: clinical trials show it reduces pogre by 24% compared to placebo. The patient reports that the disease is "slowed down", but stresses that current medicine manages the condition rather than curing it. This limitation drives many patients to look for alternatives beyond conventional neurology.
The gap with alternative medicine
In the patient community, distrust of Big Pharma is palpable. "Science became $ien$e 20 years ago", the patient notes. Options emerge such as medicinal hierba — dismissed by his neurologist —, the Coimbra Protocol (high doses of vitamin D), remyelinating supplements or essential oils. Concentrated oregano oil sells for €68.30 per 100 ml, and Quinton brand seawater generated €7.5 million in revenue in 2022. However, the scientific evidence for these therapies is scarce or nonexistent.
Pectin for the brain
The new pectin-based treatment — a soluble fiber — targets cognitive decline, a central concern for someone already facing motor problems. Although there are preliminary studies on its anti-inflammatory effect, there is no medical consensus on its usefulness in MS. The patient approaches it with skepticism: "We already know how to manage, not to cure".
The cost of hope
The search for solutions becomes a maze of expensive options with no guarantees. Between high-priced drugs and supplements with no backing, patients invest time and money in whatever promises relief. The question that remains open: where is the line between evidence-based medicine and the hope for a cure that has yet to arrive?
This article is not medical advice. Consult your specialist.
Related discussions in the forum
A patient diagnosed with primary pogre multiple sclerosis (PPMS) starts a pectin treatment tomorrow to slow cognitive decline. The diagnosis came after a subtle symptom in 2022: dragging his right foot while working. Since then, he has received Ocrelizumab (Ocrevus), a monoclonal antibody that slows the disease but fails to stop its pogre. PPMS affects roughly 15% of multiple sclerosis patients and is characterized by continuous worsening without clear relapses.
Ocrelizumab: limited effectiveness in the pogre form
Ocrelizumab is the only drug approved for PPMS, but its effectiveness is modest: clinical trials show it reduces pogre by 24% compared to placebo. The patient reports that the disease is "slowed down", but stresses that current medicine manages the condition rather than curing it. This limitation drives many patients to look for alternatives beyond conventional neurology.
The gap with alternative medicine
In the patient community, distrust of Big Pharma is palpable. "Science became $ien$e 20 years ago", the patient notes. Options emerge such as medicinal hierba — dismissed by his neurologist —, the Coimbra Protocol (high doses of vitamin D), remyelinating supplements or essential oils. Concentrated oregano oil sells for €68.30 per 100 ml, and Quinton brand seawater generated €7.5 million in revenue in 2022. However, the scientific evidence for these therapies is scarce or nonexistent.
Pectin for the brain
The new pectin-based treatment — a soluble fiber — targets cognitive decline, a central concern for someone already facing motor problems. Although there are preliminary studies on its anti-inflammatory effect, there is no medical consensus on its usefulness in MS. The patient approaches it with skepticism: "We already know how to manage, not to cure".
The cost of hope
The search for solutions becomes a maze of expensive options with no guarantees. Between high-priced drugs and supplements with no backing, patients invest time and money in whatever promises relief. The question that remains open: where is the line between evidence-based medicine and the hope for a cure that has yet to arrive?
This article is not medical advice. Consult your specialist.
Related discussions in the forum
- Hilo oficial f.c. barcelona - temporada 2025/2026 · 11792 replies
- Hilo del real madrid 2025/26. año i después de modric y cesard. el advenimiento de franco. · 82317 replies
- ME HAN PUESTO EN EL IGNORE (X) · 18664 replies
- El youtuber san ludopatrón y el bote de nocilla (hilo III) · 7997 replies
Also available in: Deutsch
Summary of a discussion on Burbuja.info - Foro de economía, actualidad y política., translated from Spanish and reviewed before publication. Read the full discussion (42 replies).
More summaries
-
Beatriz de Vicente Confirms Swinger Lifestyle, Sparking Public Outcry
Spanish lawyer Beatriz de Vicente discusses her open marriage on a podcast, igniting a fierce debate about public intimacy and swinger practices.
-
Heat traps people indoors: the walking plan that never happens
The heatwave turns summer into a stay-at-home lockdown: the plan to go out walking keeps getting postponed as forecasts announce more heat ahead.
-
Social media bombshell: the big butt dividing the forum
The big butt on social media is splitting the forum: for some it attracts short-term, for others it kills a relationship. A gym body caught between desire and rejection.
-
Forum debate over moderation and a flagged user
A police report filed against a forum participant sparks a debate about moderation: some argue that permissiveness normalizes the unacceptable.
-
Hypergamy as a playbook: the dating market as an auction
A 6'3" physique guarantees nothing: the school of thought that measures the dating market by hypergamy is back in the spotlight. Attitude weighs more than looks.
-
«Going down on women is for losers»: the endless male sex debate
A forum exchange reignites the controversy: is oral sex an act of submission or shared pleasure? An analysis of the opposing views.